Silexion Therapeutics (SLXN) Financials

Silexion Therapeutics logo
$1.44 -0.21 (-12.73%)
Closing price 04:00 PM Eastern
Extended Trading
$1.56 +0.12 (+8.33%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Silexion Therapeutics

Annual Income Statements for Silexion Therapeutics

This table shows Silexion Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-5.27 -17 -12
Consolidated Net Income / (Loss)
-5.11 -17 -12
Net Income / (Loss) Continuing Operations
-5.11 -17 -12
Total Pre-Tax Income
-5.08 -17 -12
Total Operating Income
-4.68 -13 -12
Total Gross Profit
0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
4.68 13 12
Selling, General & Admin Expense
0.97 6.76 4.49
Research & Development Expense
3.71 5.82 7.14
Total Other Income / (Expense), net
-0.40 -3.94 -0.28
Other Income / (Expense), net
-0.40 -3.94 -0.28
Income Tax Expense
0.03 0.01 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest
0.17 0.08 0.00
Basic Earnings per Share
$44.23 $394.94 $8.96
Weighted Average Basic Shares Outstanding
111.73K 41.64K 1.33M
Diluted Earnings per Share
$44.23 $394.94 $8.96
Weighted Average Diluted Shares Outstanding
111.73K 41.64K 1.33M
Weighted Average Basic & Diluted Shares Outstanding
- 8.41B 3.33B

Quarterly Income Statements for Silexion Therapeutics

This table shows Silexion Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-1.47 -1.51 -12 -1.75 -1.74 -2.50 -3.26 -4.41 -2.73 -3.55
Consolidated Net Income / (Loss)
-1.42 -1.49 -12 -1.75 -1.74 -2.50 -3.26 -4.41 -2.73 -3.55
Net Income / (Loss) Continuing Operations
-1.42 -1.49 -12 -1.75 -1.74 -2.50 -3.26 -4.41 -2.73 -3.55
Total Pre-Tax Income
-1.42 -1.49 -12 -1.75 -1.74 -2.50 -3.26 -4.41 -2.73 -3.55
Total Operating Income
-1.25 -1.39 -8.04 -1.90 -1.65 -2.28 -3.29 -4.32 -2.75 -3.68
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.03 0.06 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.03 0.06 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses
1.25 1.39 8.04 1.90 1.65 2.28 3.29 4.41 2.75 3.68
Selling, General & Admin Expense
0.29 0.62 4.82 1.03 1.06 1.27 1.14 1.03 1.38 1.47
Research & Development Expense
0.96 0.77 3.22 0.87 0.59 1.02 2.16 3.38 1.37 2.21
Total Other Income / (Expense), net
-0.17 -0.10 -3.82 0.15 -0.09 -0.22 0.00 -0.06 0.02 0.13
Other Income / (Expense), net
-0.17 -0.10 -3.82 0.15 - -0.22 - - - 0.13
Income Tax Expense
0.01 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Basic Earnings per Share
$12.29 $197.80 $274.25 ($41.96) $3.84 $43.19 $2.88 ($3.32) $0.85 $5.17
Weighted Average Basic Shares Outstanding
111.73K 7.44K 43.21K 41.64K 451.99K 57.95K 1.13M 1.33M 3.23M 687.35K
Diluted Earnings per Share
$12.29 $197.80 $274.25 ($41.96) $3.84 $43.19 $2.88 ($3.32) $0.85 $5.17
Weighted Average Diluted Shares Outstanding
111.73K 7.44K 43.21K 41.64K 451.99K 57.95K 1.13M 1.33M 3.23M 687.35K
Weighted Average Basic & Diluted Shares Outstanding
- 9.77M 14.43B 8.41B 8.69M 731.64K 3.13M 3.33B 4.19M 5.56M

Annual Cash Flow Statements for Silexion Therapeutics

This table details how cash moves in and out of Silexion Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-3.43 -3.31 4.81
Net Cash From Operating Activities
-4.53 -8.40 -11
Net Cash From Continuing Operating Activities
-4.53 -8.40 -11
Net Income / (Loss) Continuing Operations
-5.11 -17 -12
Consolidated Net Income / (Loss)
-5.11 -17 -12
Depreciation Expense
0.05 0.03 0.01
Non-Cash Adjustments To Reconcile Net Income
0.45 9.68 0.47
Changes in Operating Assets and Liabilities, net
0.08 -1.58 0.61
Net Cash From Investing Activities
0.57 -0.02 -0.01
Net Cash From Continuing Investing Activities
0.57 -0.02 -0.01
Purchase of Property, Plant & Equipment
-0.01 -0.02 -0.01
Purchase of Investments
0.00 - -0.01
Net Cash From Financing Activities
0.52 5.10 16
Net Cash From Continuing Financing Activities
0.52 5.10 16
Repayment of Debt
0.00 -0.25 -0.70
Repurchase of Common Equity
- 0.00 -0.74
Issuance of Debt
0.00 0.00 16
Issuance of Common Equity
0.00 0.00 -1.53
Other Financing Activities, net
0.00 5.35 2.57
Cash Interest Paid
0.00 0.03 0.01

Quarterly Cash Flow Statements for Silexion Therapeutics

This table details how cash moves in and out of Silexion Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents
-1.26 -1.76 -1.07 0.25 -0.74 4.97 -2.70 5.78 -3.24 -3.56 -0.19
Net Cash From Operating Activities
-1.26 -1.75 -1.07 -2.65 -2.93 -2.45 -2.51 -2.84 -3.02 -3.65 -2.93
Net Cash From Continuing Operating Activities
-1.26 -1.75 -1.07 -2.65 -2.93 -2.45 -2.51 -2.84 -3.02 -3.65 -2.93
Net Income / (Loss) Continuing Operations
-1.68 -1.42 -1.49 -12 -1.75 -1.74 -2.50 -3.26 -4.41 -2.73 -3.55
Consolidated Net Income / (Loss)
-1.68 -1.42 -1.49 -12 -1.75 -1.74 -2.50 -3.26 -4.41 -2.73 -3.55
Depreciation Expense
0.01 0.01 0.01 0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
-0.01 0.17 0.11 9.62 -0.22 0.10 0.27 0.02 0.08 0.35 0.06
Changes in Operating Assets and Liabilities, net
0.42 -0.51 0.30 -0.43 -0.95 -0.82 -0.27 0.39 1.31 -1.26 0.56
Net Cash From Investing Activities
-0.00 -0.01 - -0.02 - -0.01 -0.00 - -0.01 0.00 -0.00
Net Cash From Continuing Investing Activities
-0.00 -0.01 - -0.02 - -0.01 -0.00 - -0.01 0.00 -0.00
Net Cash From Financing Activities
- 0.00 - 2.92 2.18 7.43 -0.20 8.62 -0.22 0.08 2.74
Net Cash From Continuing Financing Activities
- 0.00 - 2.92 2.18 7.43 -0.20 8.66 -0.25 0.08 2.74
Repurchase of Common Equity
- 0.00 - - - -0.36 -0.10 -0.23 -0.05 0.00 -0.25
Issuance of Common Equity
- 0.00 - 0.62 -0.62 -0.65 -0.10 -0.65 -0.13 0.08 1.99
Other Financing Activities, net
- 0.00 - 2.30 3.05 4.14 - 3.54 -5.11 0.00 1.00

Annual Balance Sheets for Silexion Therapeutics

This table presents Silexion Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets
5.26 2.86 7.22
Total Current Assets
4.98 2.25 6.64
Cash & Equivalents
4.60 1.19 5.99
Restricted Cash
0.03 0.04 0.03
Prepaid Expenses
0.34 0.97 0.57
Other Current Assets
0.02 0.06 0.05
Plant, Property, & Equipment, net
0.05 0.03 0.03
Total Noncurrent Assets
0.23 0.58 0.55
Other Noncurrent Operating Assets
0.23 0.58 0.55
Total Liabilities & Shareholders' Equity
5.26 2.86 7.22
Total Liabilities
2.26 6.85 4.61
Total Current Liabilities
2.20 3.52 2.76
Accounts Payable
1.68 1.72 1.70
Current Employee Benefit Liabilities
0.21 0.64 0.88
Other Current Liabilities
0.31 1.16 0.18
Total Noncurrent Liabilities
0.06 3.33 1.85
Other Noncurrent Operating Liabilities
0.06 3.33 1.85
Total Equity & Noncontrolling Interests
-0.42 -3.99 2.60
Total Preferred & Common Equity
-15 -3.99 2.60
Total Common Equity
-15 -3.99 2.60
Common Stock
11 39 58
Retained Earnings
-27 -43 -55

Quarterly Balance Sheets for Silexion Therapeutics

This table presents Silexion Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets
2.53 3.09 8.31 5.80 12 4.60 4.25
Total Current Assets
2.32 3.05 7.72 5.24 11 4.07 3.74
Cash & Equivalents
1.70 1.97 6.15 3.47 9.24 2.41 2.23
Restricted Cash
0.03 0.05 0.03 0.03 0.03 0.03 0.03
Prepaid Expenses
0.53 0.94 1.48 1.68 1.74 1.53 1.37
Other Current Assets
0.07 0.08 0.06 0.06 0.05 0.10 0.11
Plant, Property, & Equipment, net
0.04 0.04 0.03 0.03 0.03 0.02 0.02
Total Noncurrent Assets
0.17 0.01 0.55 0.53 0.53 0.51 0.49
Other Noncurrent Operating Assets
0.17 0.01 0.55 0.53 0.53 0.51 0.49
Total Liabilities & Shareholders' Equity
2.53 3.09 8.31 5.80 12 4.60 4.25
Total Liabilities
2.37 7.67 5.72 5.68 4.64 4.31 4.20
Total Current Liabilities
2.36 3.58 2.40 2.15 2.79 4.06 3.98
Accounts Payable
1.66 2.66 1.62 1.35 1.89 1.76 2.16
Current Employee Benefit Liabilities
0.25 0.69 0.62 0.63 0.72 0.56 0.63
Other Current Liabilities
0.45 0.24 0.16 0.17 0.17 1.74 1.18
Total Noncurrent Liabilities
0.01 4.08 3.33 3.53 1.85 0.25 0.23
Other Noncurrent Operating Liabilities
0.01 4.08 3.33 3.53 1.85 0.25 0.23
Total Equity & Noncontrolling Interests
-3.20 -4.58 2.59 0.12 6.98 0.29 0.04
Total Preferred & Common Equity
-18 -4.58 2.59 0.12 6.98 0.29 0.04
Total Common Equity
-18 -4.58 2.59 0.12 6.98 0.29 0.04
Common Stock
11 37 48 48 58 58 61
Retained Earnings
-30 -42 -45 -47 -51 -58 -61

Annual Metrics And Ratios for Silexion Therapeutics

This table displays calculated financial ratios and metrics derived from Silexion Therapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 8,414,615,000.00 3,126,642.00
DEI Adjusted Shares Outstanding
0.00 56,097,433.00 312,664.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.30 -38.10
Growth Metrics
- - -
Revenue Growth
0.00% 0.00% 0.00%
EBITDA Growth
0.00% -227.65% 27.84%
EBIT Growth
0.00% -225.24% 27.86%
NOPAT Growth
0.00% -168.55% 7.47%
Net Income Growth
0.00% -223.39% 27.89%
EPS Growth
0.00% -223.39% -97.73%
Operating Cash Flow Growth
0.00% -85.38% -28.86%
Free Cash Flow Firm Growth
0.00% 0.00% -90.84%
Invested Capital Growth
0.00% -221.87% 34.47%
Revenue Q/Q Growth
0.00% 0.00% 100.00%
EBITDA Q/Q Growth
0.00% 0.00% -29.13%
EBIT Q/Q Growth
0.00% 0.00% -29.29%
NOPAT Q/Q Growth
0.00% 0.00% -26.28%
Net Income Q/Q Growth
0.00% 0.00% -28.82%
EPS Q/Q Growth
0.00% 0.00% 209.80%
Operating Cash Flow Q/Q Growth
0.00% -24.81% -0.84%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
0.00% 0.00% -49.00%
Profitability Metrics
- - -
Gross Margin
0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00%
Tax Burden Percent
100.63% 100.06% 100.03%
Interest Burden Percent
100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-170.21% 3,343.93% 1,718.90%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
877.76% 65,880.10% 1,718.90%
Return on Equity Simple (ROE_SIMPLE)
33.01% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.28 -8.80 -8.14
NOPAT Margin
0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-39.64% -264.27% -104.13%
Return On Investment Capital (ROIC_SIMPLE)
782.03% 220.60% -312.81%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-5.08 -17 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-5.03 -16 -12
Valuation Ratios
- - -
Price to Book Value (P/BV)
0.00 0.00 0.98
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.98
Price to Revenue (P/Rev)
0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-1.54 5.91 5.22
Leverage Ratio
1.75 -8.22 -7.27
Compound Leverage Factor
1.75 -8.22 -7.27
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
501.73% 0.00% 0.00%
Noncontrolling Interests to Total Capital
113.96% 0.00% 0.00%
Common Equity to Total Capital
-515.69% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
0.00 -40.60 -15.17
Noncontrolling Interest Sharing Ratio
615.69% -1,870.14% 0.00%
Liquidity Ratios
- - -
Current Ratio
2.27 0.64 2.41
Quick Ratio
2.09 0.34 2.17
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
0.00 -5.21 -9.94
Operating Cash Flow to CapEx
0.00% -38,163.64% -120,211.11%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
-1.62 -5.21 -3.42
Invested Capital Turnover
0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 -3.59 1.80
Enterprise Value (EV)
0.00 0.03 -3.47
Market Capitalization
0.00 1.26 2.55
Book Value per Share
($138.52) $0.00 $0.83
Tangible Book Value per Share
($138.52) $0.00 $0.83
Total Capital
3.00 -3.99 2.60
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-4.62 -1.22 -6.02
Capital Expenditures (CapEx)
-0.07 0.02 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.84 -2.50 -2.14
Debt-free Net Working Capital (DFNWC)
2.78 -1.27 3.88
Net Working Capital (NWC)
2.78 -1.27 3.88
Net Nonoperating Expense (NNE)
1.83 7.72 3.77
Net Nonoperating Obligations (NNO)
-4.62 -1.22 -6.02
Total Depreciation and Amortization (D&A)
0.05 0.03 0.01
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 $3,954.00 $89.60
Adjusted Weighted Average Basic Shares Outstanding
0.00 4.16K 132.95K
Adjusted Diluted Earnings per Share
$0.00 $3,954.00 $89.60
Adjusted Weighted Average Diluted Shares Outstanding
0.00 4.16K 132.95K
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 56.10M 333.08M
Normalized Net Operating Profit after Tax (NOPAT)
-3.28 -8.80 -8.14
Normalized NOPAT Margin
0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -6.21%

Quarterly Metrics And Ratios for Silexion Therapeutics

This table displays calculated financial ratios and metrics derived from Silexion Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding
0.00 0.00 0.00 8,414,615,000.00 8,414,615,000.00 8,692,392.00 731,642.00 3,126,642.00 3,330,785,000.00 4,189,954.00
DEI Adjusted Shares Outstanding
0.00 0.00 0.00 56,097,433.00 56,097,433.00 57,949.00 731,642.00 312,664.00 333,078,500.00 418,995.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 0.00 -0.03 -0.03 -43.19 -4.46 -14.11 -0.01 -8.48
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -4.67% -1,541.61% 0.00% -16.74% -68.72% 72.22% -145.62% -66.89% -42.09%
EBIT Growth
0.00% -5.16% -1,522.16% 0.00% -16.36% -68.12% 72.24% -147.48% -66.61% -42.04%
NOPAT Growth
0.00% 2.05% -999.32% 0.00% -32.00% -64.91% 59.03% -127.42% -66.61% -61.12%
Net Income Growth
0.00% 20.63% -1,366.01% 0.00% -21.93% -68.10% 72.50% -152.55% -57.52% -41.87%
EPS Growth
0.00% 0.00% -1,366.01% 0.00% -21.93% -68.10% -98.95% 92.09% -77.86% -88.03%
Operating Cash Flow Growth
0.00% 0.00% -287.30% -132.78% -40.01% -135.40% -7.16% -3.08% -48.63% -16.67%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% 0.00% 0.00% -66.11% -777.15% 0.00% -238.05% -1,937.11%
Invested Capital Growth
0.00% 0.00% 0.00% 0.00% 0.00% -114.85% 65.28% 34.47% 40.31% 34.32%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 83.33% -100.00% 0.00%
EBITDA Q/Q Growth
0.00% -4.96% -699.73% 85.15% 6.37% -51.70% -31.68% -31.33% 36.38% -29.16%
EBIT Q/Q Growth
0.00% -4.87% -697.44% 85.28% 5.50% -51.52% -31.68% -31.26% 36.38% -29.17%
NOPAT Q/Q Growth
0.00% -10.80% -480.22% 76.36% 13.16% -38.42% -44.13% -31.26% 36.38% -33.87%
Net Income Q/Q Growth
0.00% -4.64% -696.51% 85.27% 0.69% -44.27% -30.32% -35.25% 38.06% -29.93%
EPS Q/Q Growth
0.00% -4.64% -696.51% 85.27% 0.69% -44.27% -33.33% -215.28% 125.60% 508.24%
Operating Cash Flow Q/Q Growth
-39.38% 39.21% -149.11% -10.29% 16.17% -2.20% -13.40% -6.09% -20.89% 19.78%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 62.94% -100.00% 0.00% -91.69% -3,355.12% 27.12% 29.98% -10.60%
Invested Capital Q/Q Growth
0.00% 0.00% -320.78% 21.07% 30.92% 6.36% 32.01% -49.00% 37.07% -3.02%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,960.00% -7,850.91% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,973.33% -7,856.36% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,973.33% -7,856.36% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,873.33% -8,021.82% 0.00% 0.00%
Tax Burden Percent
100.35% 100.13% 100.02% 100.06% 100.00% 100.12% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 105.15% 100.00% 99.09% 102.11% 99.42% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% 0.00% 0.00% 3,343.93% -650.85% -13,073.26% -771.23% 1,718.90% -897.46% -17,021.95%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% 0.00% 0.00% 65,880.10% -650.85% 868,533.77% -771.23% 1,718.90% -897.46% -17,021.95%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-0.88 -0.97 -5.63 -1.33 -1.16 -1.60 -2.30 -3.02 -1.92 -2.58
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,681.33% -5,499.45% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
0.00% -60.34% -616.39% -34.12% -18.75% -34.69% -16.96% -38.32% -18.75% -33.92%
Return On Investment Capital (ROIC_SIMPLE)
- 30.30% 122.85% 33.34% -44.66% -1,332.33% -33.03% -116.20% -661.27% -5,854.55%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,783.33% 1,874.55% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7,190.00% 6,136.36% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10,973.33% 8,010.91% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-1.42 -1.49 -12 -1.75 -1.65 -2.50 -3.29 -4.32 -2.75 -3.55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-1.41 -1.48 -12 -1.76 -1.65 -2.50 -3.29 -4.32 -2.75 -3.55
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 2.88 58.68 0.55 0.98 14.21 39.84
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 2.88 58.68 0.55 0.98 14.21 39.84
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -11.25 0.44 0.31 -2.39 -19.10 -4.71 5.22 -3.00 -35.05
Leverage Ratio
0.00 16.50 -0.67 -8.22 3.21 30.48 6.13 -7.27 4.49 61.24
Compound Leverage Factor
0.00 16.50 -0.67 -8.22 3.38 30.48 6.07 -7.42 4.46 61.24
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 9,841.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 2,191.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% -11,932.68% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 0.00 -23.59 -6.69 -11.51 -5.71 -11.70 -19.01 -22.84
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% -1,870.14% 0.00% 6,743.59% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
0.00 0.98 0.85 0.64 3.22 2.44 3.97 2.41 1.00 0.94
Quick Ratio
0.00 0.72 0.55 0.34 2.57 1.61 3.32 2.17 0.59 0.56
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 0.60 0.98 0.00 2.45 0.20 -6.61 -4.82 -3.38 -3.73
Operating Cash Flow to CapEx
-29,200.00% 0.00% -16,581.25% 0.00% -40,883.33% -250,700.00% 0.00% -150,800.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
0.00 -1.57 -6.60 -5.21 -3.60 -3.37 -2.29 -3.42 -2.15 -2.21
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 -1.57 -6.60 0.00 -3.60 -1.80 4.31 1.80 1.45 1.16
Enterprise Value (EV)
0.00 0.00 1.04 0.03 1.27 3.55 -5.42 -3.47 1.69 -0.51
Market Capitalization
0.00 0.00 3.06 1.26 7.46 7.04 3.85 2.55 4.13 1.75
Book Value per Share
$0.00 ($2,453.24) ($105.96) $0.00 $0.00 $0.01 $9.54 $0.83 $0.00 $0.06
Tangible Book Value per Share
$0.00 ($2,453.24) ($105.96) $0.00 $0.00 $0.01 $9.54 $0.83 $0.00 $0.06
Total Capital
0.00 0.15 -4.58 -3.99 2.59 0.12 6.98 2.60 0.29 0.04
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -1.72 -2.02 -1.22 -6.19 -3.49 -9.27 -6.02 -2.44 -2.26
Capital Expenditures (CapEx)
0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -1.77 -2.56 -2.50 -0.86 -0.40 -1.00 -2.14 -2.44 -2.49
Debt-free Net Working Capital (DFNWC)
0.00 -0.05 -0.54 -1.27 5.33 3.09 8.27 3.88 0.01 -0.24
Net Working Capital (NWC)
0.00 -0.05 -0.54 -1.27 5.33 3.09 8.27 3.88 0.01 -0.24
Net Nonoperating Expense (NNE)
0.55 0.52 6.23 0.42 0.58 0.90 0.96 1.39 0.81 0.98
Net Nonoperating Obligations (NNO)
0.00 -1.72 -2.02 -1.22 -6.19 -3.49 -9.27 -6.02 -2.44 -2.26
Total Depreciation and Amortization (D&A)
0.01 0.01 0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $792.45 $274.05 ($6,294.00) $39.00 $43.20 $2.88 ($33.20) $8.50 $5.17
Adjusted Weighted Average Basic Shares Outstanding
0.00 1.86K 43.17K 278.00 45.20K 57.95K 1.13M 132.95K 323.04K 687.35K
Adjusted Diluted Earnings per Share
$0.00 $0.00 $274.05 ($6,294.00) $39.00 $43.20 $2.88 ($33.20) $8.50 $5.17
Adjusted Weighted Average Diluted Shares Outstanding
0.00 72.36K 43.17K 278.00 45.20K 57.95K 1.13M 132.95K 323.04K 687.35K
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($6,294.00) $0.00 $0.00 $0.00 ($33.20) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 72.36K 106.87M 56.10M 57.95K 73.16K 3.13M 333.08M 419.00K 5.56M
Normalized Net Operating Profit after Tax (NOPAT)
-0.88 -0.97 -5.63 -1.33 -1.16 -1.60 -2.30 -3.02 -1.92 -2.58
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,681.33% -5,499.45% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,873.33% -8,021.82% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% -2.15% -2.59% 0.00% -6.21% -2.93% -3.75%

Financials Breakdown Chart

Key Financial Trends

Silexion Therapeutics’ latest results show a clinical-stage company with ongoing research spending but no meaningful revenue and continued cash burn. In Q2 2026, the company reported a $3.6 million net loss and used $2.9 million in operating cash. Recent financing helped offset that outflow, but the balance sheet remained tight at quarter-end.

  • Operating cash use eased to $2.9 million in Q2 2026 from $3.6 million in Q1 2026, although it remained substantial.
  • The company generated $2.7 million in net financing cash during Q2 2026, including $2.0 million from common-stock issuance and $1.0 million from other financing activities.
  • Research and development spending was $2.2 million in Q2 2026, up from $1.4 million in Q1. This may support development efforts, but it also contributes to the company’s cash needs.
  • Revenue remains negligible: reported revenue was zero in Q1 and Q2 2026, following only $30,000 in Q3 2025 and $55,000 in Q4 2025.
  • Quarterly losses have persisted. The Q2 2026 net loss of $3.6 million was greater than the $2.7 million loss in Q1, though below the $4.4 million loss in Q4 2025. Losses were also reported throughout 2024 and 2025.
  • Cash and equivalents fell to $2.2 million at the end of Q2 2026 from $2.4 million at the end of Q1 and $9.2 million at the end of Q3 2025. Q2 cash was less than one quarter of the company’s Q2 operating cash use, underscoring reliance on future funding.
  • Liquidity was limited at quarter-end: current assets of $3.7 million were below current liabilities of $4.0 million, while total shareholders’ equity was only $44,000.
  • The company has repeatedly relied on financing as operating cash outflows continue. Further equity issuance could dilute existing shareholders; the supplied earnings-per-share and share-count figures also appear inconsistent, so they should be treated cautiously.
11/18/26 04:29 PM ETAI Generated. May Contain Errors.

Silexion Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Silexion Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Silexion Therapeutics' net income appears to be on a downward trend, with a most recent value of -$11.91 million in 2025, falling from -$5.11 million in 2023. The previous period was -$16.52 million in 2024. See Silexion Therapeutics' forecast for analyst expectations on what's next for the company.

Silexion Therapeutics' total operating income in 2025 was -$11.63 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.63 million

Over the last 2 years, Silexion Therapeutics' total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

In the past 8 quarters, Silexion Therapeutics' cash and equivalents has ranged from $1.70 million in Q2 2024 to $9.24 million in Q3 2025, and is currently $2.23 million as of their latest financial filing in Q2 2026.

Silexion Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2023.

Over the last 2 years, Silexion Therapeutics' book value per share changed from -138.52 in 2023 to 0.83 in 2025.



Financial statements for NASDAQ:SLXN last updated on 11/11/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners